Advertisement


Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Deborah Collyar: What's In It for Patients?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Advertisement